Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Remdesivir-HU in Moderate and Severe COVID-19
NCT04610541Phase 3Unknown
- Sponsor
- University of Pécs
- Start
- Oct 2020
- Primary completion
- Oct 2021
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of remdesivir in coronavirus disease 2019 (COVID-19), sponsored by University of Pécs. Primary endpoint: Safety and tolerability of REM use at 30 days. Status: unknown.
02
Drugs
remdesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04610541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04610541.